Abstract: The present invention concerns an extract from pomegranate (Punica granatum L), specifically obtained from one or more immature pomegranate fruits. This extract is obtained through an extraction process including steps a)-d) as described in the text and it may contain gallotannins, ellagitannins, ellagic acid derivatives and granatins. Pharmaceutical and nutraceutical compositions and food supplements comprising this extract fall within the scope of the present invention as well as their use in various fields, more specifically for the treatment of tumors.

Abstract: Provided is a medical compound including a synthetic flavone derivative, according to the formula (I) with allotment in position C-3 of a group as shown below: wherein at least two of R2-R6 are H, and the remaining are independently selected from: H, OH, R1, OR1, NO2, NH2, NHR1, F, Cl, Br, I, where R1 is a radical.

Abstract: A process for the conversion of a feedstock containing one or more fatty acid triglycerides to a mixture containing one or more fatty acid alkyl esters and t-alkyl glycerols, including reacting the feedstock with a compound of formula (I): R—O—RI??(I) wherein: RI is an alkyl, alkenyl or alkynyl having 1-18 carbon atoms; R is H or a tertiary alkyl group, wherein the reaction takes place in the presence of an acid transesterification catalyst by irradiation with microwaves and/or ultrasound and/or radio waves.

Abstract: The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.

Abstract: The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.

Abstract: The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.

Abstract: A process for the conversion of a feedstock containing one or more fatty acid triglycerides to a mixture containing one or more fatty acid alkyl esters and t-alkyl glycerols, including reacting the feedstock with a compound of formula (I): R—O—RI??(I) wherein: RI is an alkyl, alkenyl or alkynyl having 1-18 carbon atoms; R is H or a tertiary alkyl group, wherein the reaction takes place in the presence of an acid transesterification catalyst by irradiation with microwaves and/or ultrasound and/or radio waves.

Abstract: The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.

Abstract: The present invention relates to compounds conformationally constrained mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.

Abstract: The present invention relates to compounds conformationally constrained mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.